[go: up one dir, main page]

AU2002235764A1 - Transdermal system containing a novel high potency progestagen - Google Patents

Transdermal system containing a novel high potency progestagen

Info

Publication number
AU2002235764A1
AU2002235764A1 AU2002235764A AU3576402A AU2002235764A1 AU 2002235764 A1 AU2002235764 A1 AU 2002235764A1 AU 2002235764 A AU2002235764 A AU 2002235764A AU 3576402 A AU3576402 A AU 3576402A AU 2002235764 A1 AU2002235764 A1 AU 2002235764A1
Authority
AU
Australia
Prior art keywords
system containing
progestagen
transdermal system
novel high
high potency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235764A
Inventor
Clemens Guenther
Ralph Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2002235764A1 publication Critical patent/AU2002235764A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a matrix transdermal system containing (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,2 0-dione comprising a polyacrylate adhesive.
AU2002235764A 2000-12-21 2001-12-11 Transdermal system containing a novel high potency progestagen Abandoned AU2002235764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00250449A EP1216699A1 (en) 2000-12-21 2000-12-21 Transdermal system comprising a highly potent progestin
EP00250449.6 2000-12-21
PCT/EP2001/014538 WO2002049622A2 (en) 2000-12-21 2001-12-11 Transdermal system containing a novel high potency progestagen

Publications (1)

Publication Number Publication Date
AU2002235764A1 true AU2002235764A1 (en) 2002-07-01

Family

ID=8172629

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235764A Abandoned AU2002235764A1 (en) 2000-12-21 2001-12-11 Transdermal system containing a novel high potency progestagen

Country Status (7)

Country Link
US (1) US20030003139A1 (en)
EP (2) EP1216699A1 (en)
JP (1) JP2004525872A (en)
AT (1) ATE396713T1 (en)
AU (1) AU2002235764A1 (en)
DE (1) DE50114006D1 (en)
WO (1) WO2002049622A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (en) * 2002-07-25 2004-02-05 Schering Ag New compositions, useful as male contraceptives, comprise synergistic active agent combination of androgenic 11beta-halo-steroid and gestagenic 14 alpha, 17alpha-ethylene-estratrienone derivative
MXPA05001017A (en) * 2002-07-25 2005-06-08 Schering Ag COMPOSITION CONTAINING AN ANDROGENOUS 11beta-HALOGEN STEROID AND A PROGESTATIONAL HORMONE, AND MALE CONTRACEPTIVE BASED ON SAID COMPOSITION.
DE102010040299A1 (en) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
BR112014012444B1 (en) 2011-11-23 2021-12-14 Therapeuticsmd, Inc A PHARMACEUTICAL COMPOSITION COMPRISING SOLUBILIZED ESTRADIOL, PROGESTERONE AND A SOLUBILIZING AGENT, AND USES THEREOF TO TREAT A MENOPAUSE-RELATED SYMPTOM IN A WOMAN
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US20190343796A1 (en) * 2016-12-28 2019-11-14 Fujifilm Toyama Chemical Co., Ltd. Composition for external use
US11179469B2 (en) 2017-04-28 2021-11-23 Nitto Denko Corporation Transdermal absorption preparation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP2552716B2 (en) * 1988-10-11 1996-11-13 積水化学工業株式会社 Transdermal patch
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
DE4447401A1 (en) * 1994-12-23 1996-07-04 Schering Ag 14.17-C¶2¶-bridged steroids
DE19526864A1 (en) * 1995-07-22 1997-01-23 Labtec Gmbh Hormone patches
DE19848303A1 (en) * 1998-10-14 2000-04-20 Schering Ag Stable combination of 14,17-over-bridged steroid gestagen and cyclodextrin compound, useful for treating climacteric disorders or for contraception

Also Published As

Publication number Publication date
ATE396713T1 (en) 2008-06-15
DE50114006D1 (en) 2008-07-10
EP1343483A2 (en) 2003-09-17
US20030003139A1 (en) 2003-01-02
EP1216699A1 (en) 2002-06-26
JP2004525872A (en) 2004-08-26
EP1343483B1 (en) 2008-05-28
WO2002049622A2 (en) 2002-06-27
WO2002049622A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
AU2002235764A1 (en) Transdermal system containing a novel high potency progestagen
IL147037A0 (en) Peptide acceptor ligation methods
WO1999064047A8 (en) Novel antiviral compounds
EP1337336B8 (en) Reaction plate
AU1285300A (en) Hiv vaccine
TW200716550A (en) Pharmaceutical composition comprising ritonavir
AU7766300A (en) Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
AU3721500A (en) High pressure syringe
AU8198001A (en) Dermal for amino laevulinic acid
AP2001002220A0 (en) Calcilytic compounds.
AU2001274894A1 (en) Novel matrix metalloproteinases
AU2002220652A1 (en) Pressure-sensitive adhesive
AU7210298A (en) Use of an extract of alchemilli vulgaris
AU1932997A (en) Dosage forms and uses
AU1071901A (en) 23431, a novel human ubiquitin protease
AU2001293214A1 (en) Heatsink retainer
AU3440001A (en) Stamp adhesive
AU2002367109A1 (en) Novel crystalline tricyclic triazolobenzazepine derivative
AU2001245463A1 (en) 26583, a novel serine/threonine phosphatase and uses therefor
AU2169799A (en) Pharmaceutical composition for nasal administration of thiocolchicoside
AU5274099A (en) Hiv vaccine
WO2001032201A3 (en) A pharmaceutical composition having high cell membrane permeability
EP0634168A4 (en)
AU3181401A (en) Chemically modified hiv envelope glycoprotein
AU1490602A (en) A novel polypeptide - human branched-chain alpha-ketoacid dehydrogenase (bckdh) e1-beta subunit 9.9 and polynucleotide encoding the same